

Risika hitrangana tsy fahasalamana avy @ fanaovana vaksiny vitsivitsy

Nanongonin'i H. Mahasedra Ratsimbarison, 5 mey 2021.

Ity fanadihadina ity dia vokatry ny fahazoako manokana ireo lahatsoratra nangonina voatanisa etsy ambany sy ireo fifanakalozan-kevitra tamin'ireo rahalahy sy ireo namana mpitsabo izay isaorana manokana.

Vaksiny	Tsy fahasalamana sasany mety hitranga avy @ fanaovana vaksiny	Risika hitrangany Isan’ny tranga tsy fahasalamana miseho isaky ny dozy iray tapitrisa nomena (cas par million de doses administrées)
AstraZeneca na Vaxzevria	thrombose veineuse cérébrale (CVST)	11,88
	Tranga CVST miisa 169 no hita raha dozy 34 tapitrisa no natsindrona tao United Kingdom sy European Economic Area hatramin’ny 4 aprily 2021. Ny ankamaroany dia vehivavy latsaky ny 60 taona, izay nitrangany ao anatin’ny 2 herinandro nanindromana ny vaksiny. [1]	
	thrombose avec thrombocytopénie (TTS)	10
	Tranga TTS miisa 10 eo isaky ny dozy 1 tapitrisa ao amin’ny Fivondronambe Eoropeana (UE) hatramin’ny 16 aprily 2021. Betsaka kokoa ireo vehivavy vita vaksiny tao Eoropa ary ny ankamaroan’ireo voan’ny TTS dia vehivavy. [15 & 3]	
<p>European Medicines Agency (EMA) (7 aprily 2021): Ireo vokatsoa avy amin’ny vaksiny AstraZeneca dia mbola manatombo ny risika mety hitrangana tsy fahasalamana. Io vaksiny io dia mahomby amin’ny fisorohana ny COVID-19 sy ny fampihenana ny fidirana hopitaly sy ny fahafatesana vokatry ny COVID-19. [1]</p> <p>Fiadidina momba ny Fahasalamana ao Denmark (14 aprily 2021): Hajanona tanteraka ny fampiasana ny vaksiny AstraZeneca satria misy vaksiny hafa azo ampiasana, mbola voafehy ny fihanaky ny COVID-19 ao amin’ny firenena ary fantatra fa misy risika ny fampiasana ny vaksiny AstraZeneca na dia kely aza izany. [2]</p> <p>Ny Covishield dia mitovy singa fanefitra fototra (substance active) amin’ny AstraZeneca. [3]</p>		

Vaksiny	Tsy fahasalamana sasany mety hitranga avy @ fanaovana vaksiny	Risika hitrangany
Johnson & Johnson na Janssen	thrombose avec thrombocytopénie (TTS)	1,14
	Tranga TTS miisa 8 no hita raha dozy mihoatra ny 7 tapitrisa no natsindrona tao USA hatramin’ny 13 aprily 2021. Olona latsaky ny 60 taona avokoa, izay nitrangany ao anatin’ny 3 herinandro nanindromana ny vaksiny, vehivavy ny ankamaroany. [4]	
	thrombose avec thrombocytopénie (TTS)	1,87
	Tranga TTS miisa 15 no hita raha dozy 7,98 tapitrisa no natsindrona tao USA hatramin’ny 21 aprily 2021. Lehilahy 1 no voan’ny CVST tamin’ny dingana faha-III fanandramana ny vaksiny. Vehivavy avokoa ireo 15 voan’ny TTS: 8 manana lanja ambony (obésité); 2 mampiasa fanafody am-bava fanabeazana aizana; 2 manana hypothyroïdie 2 manana tosi-drà ambony Tsy nisy tamin’izy ireo no: bevohoka na niteraka 12 herinandro teo aloha Tamin’ireo vehivavy 15 voan’ny TTS dia: 15 no niditra hopitaly 12 no niditra réanimation 3 no nodimandry 5 no afaka nivoaka ny hopitaly Isan’ny tranga TTS niseho isaky ny dozy iray tapitrisa nomena: 7,00 hoan’ireo vehivavy 18-49 taona 0.9 hoan’ireo vehivavy mihoatra ny 50 taona. [5]	
European Medicines Agency (EMA) (7 arpily 2021): Ireo vokatsoa avy amin’ny vaksiny Janssen dia mbola mitohy ho manatombo oharina amin’ny risika mety hitranga. Io vaksiny io dia mahomby amin’ny fisorohana ny COVID-19 sy ny fampihenana ny fidirana hopitaly sy ny fahafatesana vokatry ny COVID-19. [4]		
US Centers for Disease Control and Prevention (CDC) (27 aprily 2021): Ireo modely ampiasan’ny CDC dia manombana fa ny fidirana hopitaly sy ny fahafatesana vokatry ny COVID-19 dia azo sorohana amin’ny fanohizana ny fampiasana ny vaksiny Janssen. [5]		

Vaksiny	Aretina sasany mety hitranga avy @ fanaovana vaksiny
Pfizer/BioNTech na Comirnaty	<p>EMA (29 marsa/14 aprily 2021): Tsy misy soritra ilazana fa mifandray ny fitrangana thrombocytopenie sy ny fanaovana vaksiny Pfizer. [6 & 7]</p> <p>CDC (16 aprily 2021): Misy olona vitsy nahitana tranga maherivaika (effets secondaires sévères) vokatry ny fanaovana vaksiny Pfizer; momba ny tsy fahafahana manao raharaha andavanandro ireo tranga ireo. [8]</p> <p>CDC (27 aprily 2021): Tsy nahitana tranga CVST miaraka amin'ny thrombocytopenie hatreto tamin'ireo nitsindrona vaksiny Pfizer na Moderna. [5]</p>
CDC (23 aprily 2021): Ireo vaksiny Pfizer/BioNTech , Moderna ary Johnson & Johnson ihany no nahazo alalana sy amporisihana ao USA hatreto. [9]	
Sinopharm (Beijing sy Wuhan)	Fikambanana Iraisam-pirenena momba ny Fahasalamana (OMS) (23 aprily 2021): Misy karazany 2 io vaksiny vokarin'ny Sinopharm io, izay samy mbola tsy nahazo alalana (Emergency Used Listing /Pre-qualification (EUL/PQ) approval) tamin'ny OMS ny fampiasana azy na dia efa ampiasan'ny firenena sinoa aza. [10 & 11 & 12]

Vaksiny	Aretina hafa mety hitranga	Risika hitrangany
Vaksiny hoan'ny kitroto (rougeole)	thrombocytopenie	30
OMS (Mey 2002): Raha ny antontan'isa ananana dia azo antoka ny vaksiny @ kitroto. [13]		
Vaksiny Sabin hoan'ny polio	fahalemena ara-batana (vaccine-associated paralytic polio)	0,15
OMS (Mey 2014): Na eo aza ny ny vokatsoa maro avy amin'ny vaksiny Sabin dia misy risika fahalemena mety mahazo ny ankizy indrindra indrindra amin'ny fanomezana azy voalohany. [14]		

Thrombose: fivaingan'ny rà ao amin'ny lalan-drà.

Thrombocytopenie: korontana ateraky ny fihen'ny plakety (plaquettes) ao @ rà.

Lahatsoratra nampiasana:

- [1] [AstraZeneca's COVID-19 vaccine: EMA finds possible link to very rare cases of unusual blood clots with low blood platelets](#), European Medicines Agency Press Office, 07 April 2021.
- [2] [Denmark continues its vaccine rollout without the COVID-19 vaccine from AstraZeneca](#), Danish Health Authority, 14 April 2021.
- [3] [Review of latest evidence of rare adverse blood coagulation events with AstraZeneca COVID-19 Vaccine \(Vaxzevria and Covishield\)](#), Global Advisory Committee on Vaccine Safety (GACVS) - World Health Organization (WHO), 16 April 2021.
- [4] [COVID-19 Vaccine Janssen: EMA finds possible link to very rare cases of unusual blood clots with low blood platelets](#), European Medicines Agency Press Office, 20 April 2021.
- [5] [Updated Recommendations from the Advisory Committee on Immunization Practices for Use of the Janssen \(Johnson & Johnson\) COVID-19 Vaccine After Reports of Thrombosis with Thrombocytopenia Syndrome Among Vaccine Recipients — United States, April 2021](#), Advisory Committee on Immunization Practices - US Centers for Disease Control and Prevention, April 27, 2021.
- [6 & 7] COVID-19 vaccine safety update for COMIRNATY, European Medicines Agency, [14 April 2021](#) & [29 March 2021](#).
- [8] [Pfizer-BioNTech COVID-19 Vaccine Overview and Safety](#), US Centers for Disease Control and Prevention, 16 April 2021.
- [9] [Different COVID-19 Vaccines](#), US Centers for Disease Control and Prevention, 23 April 2021.
- [10 & 11] [Sinopharm \(Beijing\)](#) & [Sinopharm \(Wuhan\)](#), McGill COVID19 Vaccine Tracker Team, 27 April 2021.
- [12] [Status of COVID-19 Vaccines within WHO EUL/PQ evaluation process](#), Strategic Advisory Group of Experts (SAGE) on Immunization - World Health Organization (WHO), 5 January 2021.
- [13] [Mass Measles Immunization Campaigns: reporting and investigating AIFI](#), Global Advisory Committee on Vaccine Safety - WHO, May 2002. On live attenuated measles vaccine, used since 1963.
- [14] [Information sheet: observed rate of vaccine reactions, polio vaccines](#), WHO Global Vaccine Safety: Essential Medicines & Health Products, May 2014.
- [15] [AstraZeneca's COVID-19 vaccine: benefits and risks in context](#), European Medicines Agency Press Office, 23 April 2021.